personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Treatment of myopic choroidal neovascularization with bevacizumab: 5 year results

Session Details

Session Title: Quick Fire Free Paper Session 04

Session Date/Time: Sunday 29/09/2013 | 11:00-13:00

Paper Time: 12:10

Venue: Hall C (Level 1)

First Author: P.Amat-Peral SPAIN

Co Author(s):    F. Lugo-Quintas   C. De La Vega Galiana   J. Montero-Moreno   J. Ruiz-Moreno     

Abstract Details

Purpose:

To evaluate the anatomic and functional response at 5 years on myopic juxta or subfoveal choroidal neovascularization (CNV) treated with bevacizumab.

Setting:

Vissum Alicante (Spain)

Methods:

A pilot, prospective, comparative, nonrandomized, consecutive and interventional study of 19 patients treated with 1.25 mg of bevacizumab for myopic subfoveal or juxtafoveal CNV. Two treatment groups: Group 1, 9 consecutive eyes treated with one intravitreal injection, Group 2, 10 eyes treated with three consecutive monthly intravitreal injections. After that, intravitreal injections were performed when CNV activity was detected in both groups (PRN). Fundus autofluorescence (FA) was performed on the study eye.

Results:

There was an average gain of 2.84 letters in BCVA at 60 months, however, this improvement was not statistically significant (p = 0.21). FA showed changes at the retinal pigment epithelium. There was statistically significant improvement in BCVA at 12 months (p = 0.001), at 24 months (p = 0.01) and 48 months (p = 0.023). The mean number of injections performed was 1.9 in Group 1 versus 3.8 in Group 2 and the number of re-injections performed after the initial protocol was 0.9 vs 0.8, respectively.

Conclusions:

Both protocols achieve similar results in terms of improvement in BCVA at 5 years, although the Group 1 requires fewer injections.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy